Mamoura Diversified Global Holding PJSC's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) ยท filed Jan 13, 2023
- Accession no.
- 0001387131-23-000335
- Filed
- Jan 13, 2023, 4:19 PM ET
- Trade date
- Dec 23, 2022-Jan 10, 2023
- Filing delay
- 21 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 11 non-derivative transactions. Open-market purchases total $7.73M. It was filed 21 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mamoura Diversified Global Holding PJSCCIK 0001419351 | 10% Owner |
| Mubadala Investment Co PJSCCIK 0001704268 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 23, 2022 | Class A Common Stock | PPurchaseAcquired | +100,378 | $7.52F2 | +$754,420.97 | 11,392,315 | Indirect | |
| Dec 27, 2022 | Class A Common Stock | PPurchaseAcquired | +145,652 | $7.24F3 | +$1,054,403.96 | 11,537,967 | Indirect | |
| Dec 28, 2022 | Class A Common Stock | PPurchaseAcquired | +71,299 | $7.18F4 | +$511,898.3 | 11,609,266 | Indirect | |
| Dec 29, 2022 | Class A Common Stock | PPurchaseAcquired | +84,622 | $7.71F5 | +$652,774.11 | 11,693,888 | Indirect | |
| Dec 30, 2022 | Class A Common Stock | PPurchaseAcquired | +99,754 | $7.55F6 | +$753,621.52 | 11,793,642 | Indirect | |
| Jan 3, 2023 | Class A Common Stock | PPurchaseAcquired | +141,646 | $7.50F7 | +$1,063,010.74 | 11,935,288 | Indirect | |
| Jan 4, 2023 | Class A Common Stock | PPurchaseAcquired | +91,892 | $7.80F8 | +$716,877.06 | 12,027,180 | Indirect | |
| Jan 5, 2023 | Class A Common Stock | PPurchaseAcquired | +80,035 | $7.38F9 | +$590,554.25 | 12,107,215 | Indirect | |
| Jan 6, 2023 | Class A Common Stock | PPurchaseAcquired | +68,953 | $7.41F10 | +$510,610.76 | 12,176,168 | Indirect | |
| Jan 9, 2023 | Class A Common Stock | PPurchaseAcquired | +76,046 | $7.64F11 | +$580,839.35 | 12,252,214 | Indirect | |
| Jan 10, 2023 | Class A Common Stock | PPurchaseAcquired | +69,518 | $7.72F12 | +$536,845.8 | 12,321,732 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.70, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (12) to this Form4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.61, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.07 to $7.32, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.25 to $7.91, inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.72, inclusive.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.83, inclusive.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $7.88, inclusive.
Referenced by the price of 1 transaction in Table I.
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.75, inclusive.
Referenced by the price of 1 transaction in Table I.
- F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 to $8.00, inclusive.
Referenced by the price of 1 transaction in Table I.
- F11
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.43 to $8.00, inclusive.
Referenced by the price of 1 transaction in Table I.
- F12
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $8.00, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
17. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.